FDA Advisory Panels Consider ADHD Treatments

Two FDA advisory panels are meeting today to consider the risks and benefits of an attention deficit hyperactivity disorder (ADHD) drug formulated to deter abuse.

The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee is reviewing Arbor Pharmaceuticals’ new drug application for amphetamine sulfate immediate-release oral capsules for treatment of ADHD.

The expert panels are weighing the drug’s risks and benefits, including potential public health impacts and whether the evidence supports abuse-deterrent labeling.